205 related articles for article (PubMed ID: 35325006)
1. Loss of Tpl2 activates compensatory signaling and resistance to EGFR/MET dual inhibition in v-RAS transduced keratinocytes.
Kelley MB; Geddes TJ; Ochiai M; Lampl NM; Kothmann WW; Fierstein SR; Kent V; DeCicco-Skinner K
PLoS One; 2022; 17(3):e0266017. PubMed ID: 35325006
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of HGF/MET signaling decreases overall tumor burden and blocks malignant conversion in Tpl2-related skin cancer.
Bonan NF; Kowalski D; Kudlac K; Flaherty K; Gwilliam JC; Falkenberg LG; Maradiaga E; DeCicco-Skinner KL
Oncogenesis; 2019 Jan; 8(1):1. PubMed ID: 30631034
[TBL] [Abstract][Full Text] [Related]
3. MET signaling in keratinocytes activates EGFR and initiates squamous carcinogenesis.
Cataisson C; Michalowski AM; Shibuya K; Ryscavage A; Klosterman M; Wright L; Dubois W; Liu F; Zhuang A; Rodrigues KB; Hoover S; Dwyer J; Simpson MR; Merlino G; Yuspa SH
Sci Signal; 2016 Jun; 9(433):ra62. PubMed ID: 27330189
[TBL] [Abstract][Full Text] [Related]
4. FGFR Inhibition Overcomes Resistance to EGFR-targeted Therapy in Epithelial-like Cutaneous Carcinoma.
Bernat-Peguera A; Navarro-Ventura J; Lorenzo-Sanz L; da Silva-Diz V; Bosio M; Palomero L; Penin RM; Pérez Sidelnikova D; Bermejo JO; Taberna M; Vilariño N; Piulats JM; Mesia R; Viñals JM; González-Suárez E; Capella-Gutierrez S; Villanueva A; Viñals F; Muñoz P
Clin Cancer Res; 2021 Mar; 27(5):1491-1504. PubMed ID: 33262138
[TBL] [Abstract][Full Text] [Related]
5. Tpl2 knockout keratinocytes have increased biomarkers for invasion and metastasis.
Decicco-Skinner KL; Jung SA; Tabib T; Gwilliam JC; Alexander H; Goodheart SE; Merchant AS; Shan M; Garber C; Wiest JS
Carcinogenesis; 2013 Dec; 34(12):2789-98. PubMed ID: 24067898
[TBL] [Abstract][Full Text] [Related]
6. Targeted disruption of the epidermal growth factor receptor impairs growth of squamous papillomas expressing the v-ras(Ha) oncogene but does not block in vitro keratinocyte responses to oncogenic ras.
Dlugosz AA; Hansen L; Cheng C; Alexander N; Denning MF; Threadgill DW; Magnuson T; Coffey RJ; Yuspa SH
Cancer Res; 1997 Aug; 57(15):3180-8. PubMed ID: 9242447
[TBL] [Abstract][Full Text] [Related]
7. Modeling the transcriptional consequences of epidermal growth factor receptor ablation in Ras-initiated squamous cancer.
Wright LN; Ryscavage A; Merlino G; Yuspa SH
Clin Cancer Res; 2012 Jan; 18(1):170-83. PubMed ID: 22068661
[TBL] [Abstract][Full Text] [Related]
8. Activation of the epidermal growth factor receptor signal transduction pathway stimulates tyrosine phosphorylation of protein kinase C delta.
Denning MF; Dlugosz AA; Threadgill DW; Magnuson T; Yuspa SH
J Biol Chem; 1996 Mar; 271(10):5325-31. PubMed ID: 8621384
[TBL] [Abstract][Full Text] [Related]
9. HER kinase activation confers resistance to MET tyrosine kinase inhibition in MET oncogene-addicted gastric cancer cells.
Bachleitner-Hofmann T; Sun MY; Chen CT; Tang L; Song L; Zeng Z; Shah M; Christensen JG; Rosen N; Solit DB; Weiser MR
Mol Cancer Ther; 2008 Nov; 7(11):3499-508. PubMed ID: 18974395
[TBL] [Abstract][Full Text] [Related]
10. Epidermal growth factor receptor (EGFR) and squamous cell carcinoma of the skin: molecular bases for EGFR-targeted therapy.
Uribe P; Gonzalez S
Pathol Res Pract; 2011 Jun; 207(6):337-42. PubMed ID: 21531084
[TBL] [Abstract][Full Text] [Related]
11. Altered prostanoid signaling contributes to increased skin tumorigenesis in Tpl2 knockout mice.
DeCicco-Skinner KL; Nolan SJ; Deshpande MM; Trovato EL; Dempsey TA; Wiest JS
PLoS One; 2013; 8(2):e56212. PubMed ID: 23457529
[TBL] [Abstract][Full Text] [Related]
12. TPL2 Is an Oncogenic Driver in Keratocanthoma and Squamous Cell Carcinoma.
Lee JH; Lee JH; Lee SH; Do SI; Cho SD; Forslund O; Inn KS; Lee JS; Deng FM; Melamed J; Jung JU; Jeong JH
Cancer Res; 2016 Nov; 76(22):6712-6722. PubMed ID: 27503930
[TBL] [Abstract][Full Text] [Related]
13. Tumor immune escape by the loss of homeostatic chemokine expression.
Pivarcsi A; Müller A; Hippe A; Rieker J; van Lierop A; Steinhoff M; Seeliger S; Kubitza R; Pippirs U; Meller S; Gerber PA; Liersch R; Buenemann E; Sonkoly E; Wiesner U; Hoffmann TK; Schneider L; Piekorz R; Enderlein E; Reifenberger J; Rohr UP; Haas R; Boukamp P; Haase I; Nürnberg B; Ruzicka T; Zlotnik A; Homey B
Proc Natl Acad Sci U S A; 2007 Nov; 104(48):19055-60. PubMed ID: 18025475
[TBL] [Abstract][Full Text] [Related]
14. ROCK2/ras
Masre SF; Rath N; Olson MF; Greenhalgh DA
Oncogene; 2017 May; 36(18):2529-2542. PubMed ID: 27991921
[TBL] [Abstract][Full Text] [Related]
15. Mig6 is a negative regulator of EGF receptor-mediated skin morphogenesis and tumor formation.
Ferby I; Reschke M; Kudlacek O; Knyazev P; Pantè G; Amann K; Sommergruber W; Kraut N; Ullrich A; Fässler R; Klein R
Nat Med; 2006 May; 12(5):568-73. PubMed ID: 16648858
[TBL] [Abstract][Full Text] [Related]
16. Up-regulation of vascular endothelial growth factor/vascular permeability factor in mouse skin carcinogenesis correlates with malignant progression state and activated H-ras expression levels.
Larcher F; Robles AI; Duran H; Murillas R; Quintanilla M; Cano A; Conti CJ; Jorcano JL
Cancer Res; 1996 Dec; 56(23):5391-6. PubMed ID: 8968091
[TBL] [Abstract][Full Text] [Related]
17. TPL2 enforces RAS-induced inflammatory signaling and is activated by point mutations.
Dodhiawala PB; Khurana N; Zhang D; Cheng Y; Li L; Wei Q; Seehra K; Jiang H; Grierson PM; Wang-Gillam A; Lim KH
J Clin Invest; 2020 Sep; 130(9):4771-4790. PubMed ID: 32573499
[TBL] [Abstract][Full Text] [Related]
18. Dual blockade of EGFR and c-Met abrogates redundant signaling and proliferation in head and neck carcinoma cells.
Xu H; Stabile LP; Gubish CT; Gooding WE; Grandis JR; Siegfried JM
Clin Cancer Res; 2011 Jul; 17(13):4425-38. PubMed ID: 21622718
[TBL] [Abstract][Full Text] [Related]
19. Suppression of epidermal growth factor receptor, mitogen-activated protein kinase, and Pak1 pathways and invasiveness of human cutaneous squamous cancer cells by the tyrosine kinase inhibitor ZD1839 (Iressa).
Barnes CJ; Bagheri-Yarmand R; Mandal M; Yang Z; Clayman GL; Hong WK; Kumar R
Mol Cancer Ther; 2003 Apr; 2(4):345-51. PubMed ID: 12700278
[TBL] [Abstract][Full Text] [Related]
20. Fibroblast growth factor receptor promotes progression of cutaneous squamous cell carcinoma.
Khandelwal AR; Kent B; Hillary S; Alam MM; Ma X; Gu X; DiGiovanni J; Nathan CO
Mol Carcinog; 2019 Oct; 58(10):1715-1725. PubMed ID: 31254372
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
